ReCon Chat with Bob...
Health Care: Drugs
Aastrom Biosciences Inc. (ASTM: NASDAQ)
$0.56 -0.01 | -1.75%
05/23/13 - 03:59 PM ET
Company Balance Sheet
| Dec 2012 | Dec 2011 | Dec 2010 | Jun 2010 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 13.64M | 5.53M | 31.25M | 14.12M |
| Receivables | 28.00K | 9.00K | 25.00K | 16.00K |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 324.00K | 636.00K | 426.00K | 383.00K |
| Total Current Assets | 13.99M | 6.18M | 31.70M | 19.52M |
| Property, Plant & Equipment, Gross | 4.79M | 5.70M | 5.02M | 4.66M |
| Accumulated Depreciation & Depletion | 3.60M | 4.14M | 3.89M | 3.65M |
| Property, Plant & Equipment, Net | 1.19M | 1.56M | 1.13M | 1.01M |
| Intangibles | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Assets | 1.19M | 1.56M | 1.13M | 1.01M |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 15.18M | 7.74M | 32.83M | 20.53M |
| Accounts Payable | 2.84M | 2.24M | 2.90M | 1.75M |
| Short Term Debt | 34.00K | 40.00K | 214.00K | 226.00K |
| Other Current Liabilities | 2.00M | 16.62M | 25.95M | 0.00 |
| Total Current Liabilities | 5.66M | 20.67M | 29.86M | 2.66M |
| Long Term Debt | 6.00K | 40.00K | 41.00K | 79.00K |
| Deferred Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Liabilities | 0.00 | 0.00 | 0.00 | 0.00 |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 41.62M | 40.00K | 41.00K | 79.00K |
| Total Liabilities | 47.28M | 20.71M | 29.90M | 2.74M |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | -32.10M | -12.97M | 2.92M | 17.79M |
| Common Par | 0.00 | 0.00 | 0.00 | 0.00 |
| Additional Paid In Capital | 243.22M | 228.88M | 225.10M | 231.34M |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -275.32M | -241.85M | -222.18M | -213.55M |
| Treasury Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Equity Adjustments | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Capitalization | -32.09M | -12.93M | 2.96M | 17.87M |
| Total Equity | -32.10M | -12.97M | 2.92M | 17.79M |
| Total Liabilities & Stock Equity | 15.18M | 7.74M | 32.83M | 20.53M |
| Total Common Shares Outstanding | 43.78M | 38.64M | 38.62M | 28.26M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic Weighted Shares Outstanding | 41.20M | 38.63M | 29.19M | 24.73M |
| Diluted Weighted Shares Outstanding | 41.20M | 38.63M | 29.19M | 24.73M |
| Number of Employees | 77 | 71 | 54 | 45 |
| Number of Part-Time Employees | 0 | 0 | 0 | 0 |
Portfolios with ASTM
- Portfolio NameUser Type
- ContributorStocks Under-$10 Setting Up...
- UserMark
- UserMy Portfolio As of 7/15/2012
- Userdonnieny7 Portfolio 1 Specu...
- ContributorBreakout Stocks Of The Week...
- Contributor10 Cheap Biotech Stocks Tha...
- Usermrtimrx WatchList
- UserMy Folly
- Userbosw119
- Usergellis1360 Portfolio 1
Latest ASTM Headlines from TheStreet
- Aastrom Biosciences Reports First Quarter 2013 Financial Results 05.08.13 | 04:05 pm
- Aastrom To Host First Quarter 2013 Investor Call On May 8, 2013 05.03.13 | 04:05 pm
- Aastrom To Hold Annual Meeting Of Shareholders On May 2, 2013 04.25.13 | 04:04 pm
- Aastrom Biosciences Announces First Patients Treated In IxCELL-DCM Clinical Study Of Ixmyelocel-T 04.19.13 | 09:04 am
- Aastrom Biosciences To Present At Multiple Conferences In April 04.09.13 | 04:04 pm
- Aastrom Biosciences Announces First Patients Enrolled In IxCELL-DCM Phase 2b Clinical Trial Of Ixmyelocel-T 04.04.13 | 09:04 am
- Aastrom Biosciences Announces Strategic Change In Research And Development Programs To Focus On Dilated Cardiomyopathy And Other Rare Disease Indications 03.27.13 | 08:03 am
- Aastrom Biosciences Reports Fourth-Quarter And Year-End 2012 Financial Results 03.18.13 | 04:03 pm
- Aastrom To Host Fourth Quarter 2012 Investor Call On March 18, 2013 03.12.13 | 04:03 pm
- Aastrom Board Of Directors Names Dominick C. Colangelo President And Chief Executive Officer 03.06.13 | 04:03 pm
Press Releases for ASTM
Partner Headlines for ASTM
- Is Takeda Interested In Aastrom Bio? - Seeking Alpha 02.27.13 | 09:02 am
- Seven Innovative Biotechs That Could Soar by Year-End: George Zavoico - NASDAQ 09.13.12 | 05:09 pm
- Cell Therapy Outlook Starting To Match Clinical Results - Seeking Alpha 08.21.12 | 09:08 am
- Talisman Energy UPGRADED to Buy and 2 Analyst-Upgraded Shares to Notice - Wall St. Cheat Sheet 07.24.12 | 06:07 am
- Analysts Release These New Equity Ratings Monday - Wall St. Cheat Sheet 06.04.12 | 03:06 am
- Follow the Analyst Leader: New Stock Coverage to Watch - Wall St. Cheat Sheet 05.31.12 | 04:05 am
- Medgenics Moving In Record Time - Seeking Alpha 05.21.12 | 09:05 am
- Aastrom Biosciences Announces Initiation of Patient Enrollment in REVIVE Phase 3 Clinical Trial of Ixmyelocel-T - Benzinga 02.29.12 | 04:02 pm
- 10 Biotech Stocks Undervalued By Levered Free Cash Flows - Seeking Alpha 12.07.11 | 08:12 am
- Aastrom Bio: Final RESTORE Data Looks Solid - Seeking Alpha 11.15.11 | 09:11 am
